![Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML](https://www.mdpi.com/biomolecules/biomolecules-10-01387/article_deploy/html/images/biomolecules-10-01387-g001.png)
Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML
![Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data - Clinical Lymphoma, Myeloma and Leukemia Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data - Clinical Lymphoma, Myeloma and Leukemia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/537b0efd-b55e-413f-bb35-9d1e7f18bd3c/gr1_lrg.jpg)
Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data - Clinical Lymphoma, Myeloma and Leukemia
![US20170137528A1 - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents US20170137528A1 - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents](https://patentimages.storage.googleapis.com/57/01/9c/e44c8fb83ae3ed/US20170137528A1-20170518-D00007.png)
US20170137528A1 - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents
![Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020) Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020)](https://jnccn.org/view/journals/jnccn/18/12.5/full-jnccn20-5043f1.jpg)
Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020)
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
![Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients](https://www.frontiersin.org/files/Articles/575168/fonc-10-575168-HTML/image_m/fonc-10-575168-t002.jpg)
Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
![Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis - Journal of the Neurological Sciences Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis - Journal of the Neurological Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/81ea0360-383c-467c-9443-bd82ff7868fb/gr1.jpg)
Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis - Journal of the Neurological Sciences
![Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients](https://www.frontiersin.org/files/Articles/575168/fonc-10-575168-HTML/image_m/fonc-10-575168-g001.jpg)
Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
![A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d0668b16-6f13-4a1b-99c6-7416a2f7b1b3/ctm2346-fig-0002-m.jpg)
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
![Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-98803-1/MediaObjects/41598_2021_98803_Fig1_HTML.png)